Reunanen S, Ghemtio L, Patel JZ, Patel DR, Airavaara K, Yli-Kauhaluoma J, et al.. Targeting Bacterial and Human Levodopa Decarboxylases for Improved Drug Treatment of Parkinson's Disease: Discovery and Characterization of New Inhibitors. European Journal of Pharmaceutical Sciences [Internet]. 2025;:107133. https://authors.elsevier.com/sd/article/S0928-0987(25)00132-0

Niemelä A, Giorgi L, Nouri S, Yurtta? B, Rauniyar K, Jeltsch M, et al.. Gliflozins, sucrose and flavonoids are allosteric activators of lecithin-cholesterol acyltransferase. Scientific Reports [Internet]. 2024;14(1):26085. https://www.nature.com/articles/s41598-024-77104-3

Johns SC, Yin X, Jeltsch M, Bishop JR, Schuksz M, Ghazal REl, et al.. Functional Importance of a Proteoglycan Co-Receptor in Pathologic Lymphangiogenesis. Circulation Research [Internet]. 2016;119(2):210-221. http://circres.ahajournals.org/content/early/2016/05/25/CIRCRESAHA.116.308504

Saharinen P, Jeltsch M, Santoyo MM, Leppänen V-M, Alitalo K. The TIE Receptor Family. In: Wheeler DL, Yarden Y. Receptor Tyrosine Kinases: Family and Subfamilies [Internet]. Springer International Publishing; 2015. pp. 743-775. https://link.springer.com/content/pdf/10.1007%2F978-3-319-11888-8_16.pdf

Anisimov A, Tvorogov D, Alitalo A, Leppänen V-M, An Y, Han EC, et al.. Vascular endothelial growth factor-angiopoietin chimera with improved properties for therapeutic angiogenesis. Circulation. 2013;127(4):424-434. 

Krebs R, Tikkanen JM, Ropponen JO, Jeltsch M, Jokinen JJ, Ylä-Herttuala S, et al.. Critical role of VEGF-C/VEGFR-3 signaling in innate and adaptive immune responses in experimental obliterative bronchiolitis. Am J Pathol. 2012;181(5):1607-20. 

Leppänen V-M, Jeltsch M, Anisimov A, Tvorogov D, Aho K, Kalkkinen N, et al.. Structural determinants of vascular endothelial growth factor-D receptor binding and specificity. Blood [Internet]. 2011;117(5):1507 - 15. http://view.ncbi.nlm.nih.gov/pubmed/21148085

Krebs R, Tikkanen JM, Ropponen JO, Jeltsch M, Jokinen JJ, Ylä-Herttuala S, et al.. VEGF-C/VEGFR-3 Signaling Regulates Inflammatory Response in Development of Obliterative Airway Disease. Journal of Heart and Lung Transplantation. 2011;30:S118 - S118. 

Bry M, Kivelä R, Holopainen T, Anisimov A, Tammela T, Soronen J, et al.. Vascular endothelial growth factor-B acts as a coronary growth factor in transgenic rats without inducing angiogenesis, vascular leak, or inflammation. Circulation [Internet]. 2010;122(17):1725 - 33. http://view.ncbi.nlm.nih.gov/pubmed/20937974

Anisimov A, Alitalo A, Korpisalo P, Soronen J, Kaijalainen S, Leppänen V-M, et al.. Activated forms of VEGF-C and VEGF-D provide improved vascular function in skeletal muscle. Circ Res [Internet]. 2009;104(11):1302 - 12. http://view.ncbi.nlm.nih.gov/pubmed/19443835

Karpanen T, Bry M, Ollila HM, Seppänen-Laakso T, Liimatta E, Leskinen H, et al.. Overexpression of vascular endothelial growth factor-B in mouse heart alters cardiac lipid metabolism and induces myocardial hypertrophy. Circ Res [Internet]. 2008;103(9):1018 - 26. http://view.ncbi.nlm.nih.gov/pubmed/18757827

Heckman CA, Holopainen T, Wirzenius M, Keskitalo S, Jeltsch M, Ylä-Herttuala S, et al.. The tyrosine kinase inhibitor cediranib blocks ligand-induced vascular endothelial growth factor receptor-3 activity and lymphangiogenesis. Cancer Res [Internet]. 2008;68(12):4754 - 62. http://view.ncbi.nlm.nih.gov/pubmed/18559522

Tammela T, He Y, Lyytikkä J, Jeltsch M, Markkanen J, Pajusola K, et al.. Distinct architecture of lymphatic vessels induced by chimeric vascular endothelial growth factor-C/vascular endothelial growth factor heparin-binding domain fusion proteins. Circ Res [Internet]. 2007;100(10):1468 - 75. http://view.ncbi.nlm.nih.gov/pubmed/17478733

Keskitalo S, Tammela T, Lyytikka J, Karpanen T, Jeltsch M, Markkanen J, et al.. Enhanced capillary formation stimulated by a chimeric vascular endothelial growth factor/vascular endothelial growth factor-C silk domain fusion protein. Circ Res [Internet]. 2007;100(10):1460 - 7. http://view.ncbi.nlm.nih.gov/pubmed/17478734

Baluk P, Tammela T, Ator E, Lyubynska N, Achen MG, Hicklin DJ, et al.. Pathogenesis of persistent lymphatic vessel hyperplasia in chronic airway inflammation. J Clin Invest [Internet]. 2005;115(2):247 - 57. http://view.ncbi.nlm.nih.gov/pubmed/15668734

He Y, Rajantie I, Pajusola K, Jeltsch M, Holopainen T, Yla-Herttuala S, et al.. Vascular endothelial cell growth factor receptor 3-mediated activation of lymphatic endothelium is crucial for tumor cell entry and spread via lymphatic vessels. Cancer Res [Internet]. 2005;65(11):4739 - 46. http://view.ncbi.nlm.nih.gov/pubmed/15930292

Saaristo A, Veikkola T, Enholm B, Hytönen M, Arola J, Pajusola K, et al.. Adenoviral VEGF-C overexpression induces blood vessel enlargement, tortuosity, and leakiness but no sprouting angiogenesis in the skin or mucous membranes. FASEB J [Internet]. 2002;16(9):1041 - 9. http://view.ncbi.nlm.nih.gov/pubmed/12087065

Enholm B, Karpanen T, Jeltsch M, Kubo H, Stenback F, Prevo R, et al.. Adenoviral expression of vascular endothelial growth factor-C induces lymphangiogenesis in the skin. Circ Res [Internet]. 2001;88(6):623 - 9. http://view.ncbi.nlm.nih.gov/pubmed/11282897

Hiltunen MO, Laitinen M, Turunen MP, Jeltsch M, Hartikainen J, Rissanen TT, et al.. Intravascular adenovirus-mediated VEGF-C gene transfer reduces neointima formation in balloon-denuded rabbit aorta. Circulation [Internet]. 2000;102(18):2262 - 8. http://view.ncbi.nlm.nih.gov/pubmed/11056103